Mergers & Acquisitions ruling the Indian Pharma market too?

Lupin Ltd., India's second-largest drugmaker by market value, and Cipla Ltd. are among companies that bid for UCB SA's U.S. generic-drug business. The Indian companies submitted first-round offers for UCB's Kremers Urban Pharmaceuticals Inc. unit in late April. The business could be valued at about $1 billion. The Brussels-based drugmaker is selling Kremers Urban as it focuses on drugs for central nervous system illnesses and immunology.

Indian drugmakers have been considering acquisitions to better compete with market leader Sun Pharmaceutical Industries Ltd after it acquired domestic rival Ranbaxy Laboratories Ltd. Dr. Reddy's Laboratories Ltd., based in Hyderabad, has already agreed to buy UCB's brands in India for 118 million euros ($129 million).

Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

PHYTOCON 2018 - Commercialization of medicinal plant products: Lab techniques to trade_14 April 2018